DFO
PRCT icon

Duquesne Family Office’s Procept Biorobotics PRCT Stock Holding History

Duquesne Family Office’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-39,266
Closed -$1.28M – 69
2022
Q2 		$1.28M Sell
39,266
-1,088,775
-97% -$39.6M 0.09% 38
2022
Q1 		$39.5M Sell
1,128,041
-532,394
-32% -$12.8M 1.71% 14
2021
Q4 		$41.5M Buy
1,660,435
+1,060,435
+177% +$39.2M 1.51% 17
2021
Q3 		$22.9M Buy
+600,000
New +$23M 0.74% 30

Other funds holding PRCT

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Duquesne Family Office's PRCT Position: Q3 2022 in Review

Duquesne Family Office sold out of Procept Biorobotics (PRCT) in Q3 2022, closing a stake of 39,266 shares — an estimated $1.28M sold.

Duquesne Family Office first reported a position in PRCT in Q3 2021 and held it in 4 quarters. The position peaked at $41.5M in Q4 2021. 103 funds tracked by Wall St. Rank hold PRCT as of Q3 2022.

  • Duquesne Family Office reported no remaining Procept Biorobotics position as of Q3 2022 after selling out during the quarter.
  • Duquesne Family Office sold 39,266 Procept Biorobotics shares in Q3 2022, an estimated $1.28M.
  • Duquesne Family Office first reported a position in Procept Biorobotics in Q3 2021 and held it in 4 quarters.
  • Duquesne Family Office's Procept Biorobotics position peaked at $41.5M in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2022.

Based on Duquesne Family Office's 13F filing for Q3 2022, filed 14 Nov 2022.